AB SCIEX Announces In Vitro Diagnostic Devices CE Marked for Europe

Company to meet European regulatory requirements for use in clinical laboratories and hospitals

AB SCIEX Announces Diagnostic Devices CE Marked for Europe

AB SCIEX

[email protected]

AB SCIEX, a global leader in analytical technologies, today announced the launch of the 3200MD CE-IVDD series for general diagnostic use in Europe.

Meeting regulatory requirements to obtain the CE-IVDD mark for the new AB SCIEX API 3200MD™ and 3200MD QTRAP LC/MS/MS systems* will provide European hospitals and clinical diagnostic laboratories the confidence to use these mass spectrometry-based systems to improve the quality of results in clinical analysis while reducing costs.

“We are focused on meeting the medical, technological and compliance needs of clinical diagnostic laboratories and hospitals,” said . “The use of LC/MS/MS technology for clinical diagnostics has already been proven to deliver faster, more accurate results at lower cost compared to existing technologies. Now, we are bringing these benefits to Europe in a way that will simplify and accelerate adoption of this powerful technology.”

Today’s news announcement at the EuroMedLab conference in Milan, Italy follows on the heels of the company’s announcement of the family of 3200MD systems earlier this year. The 3200MD series is the company’s first of a family of diagnostic devices. The intended use of these devices is to identify inorganic or organic compounds in human specimens for clinical use.

AB SCIEX plans to continue to roll out regulatory-compliant systems around the world in the future. With these IVD devices, the company is delivering on its strategy to expand the use of its technology in clinical diagnostics, which is widely deemed a new frontier for mass spectrometry.

AB SCIEX has a two-decade track record of success in the clinical research (RUO) market. The company has excelled at advancing and simplifying LC/MS/MS technology, so it is easier for laboratories to adopt and utilize for routine analysis. The robustness and ease of use of the 3200 product line makes it a preferred instrument for research laboratories of all sizes. Now applying its expertise and experience to the IVD market, AB SCIEX is also expanding its service offerings to provide enhanced service and support specifically for clinical diagnostics.

The AB SCIEX API 3200MD™ and 3200MD QTRAP LC/MS/MS systems are expected to ship in Europe by mid-June.

* Contact a local AB SCIEX representative for more information.

AB SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to push the limits in their field and address the complex analytical challenges they face. The company’s global leadership and world-class service and support in the mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With 30 years of proven innovation, AB SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information about the company, go to . Follow AB SCIEX on Twitter , and .

© 2013. AB SCIEX. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX is being used under license. IVD-MKT-12-0601-A

Suggested Articles

Nearly 10,000 patients involved in research studies were impacted by a third-party privacy breach that may have exposed their medical diagnoses.

Veterans Health Administration medical facilities currently have a paper medical record backlog that if stacked up would be 5.15 miles high, according to the…

The Department of Health and Human Services announced proposed changes to privacy restrictions on patients' substance use treatment records.